CN103245784A - 肺癌的诊断分析法 - Google Patents
肺癌的诊断分析法 Download PDFInfo
- Publication number
- CN103245784A CN103245784A CN2013100906331A CN201310090633A CN103245784A CN 103245784 A CN103245784 A CN 103245784A CN 2013100906331 A CN2013100906331 A CN 2013100906331A CN 201310090633 A CN201310090633 A CN 201310090633A CN 103245784 A CN103245784 A CN 103245784A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- group
- patient
- sample
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 137
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 134
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 134
- 238000003556 assay Methods 0.000 title abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 67
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 238000012216 screening Methods 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 55
- 239000000090 biomarker Substances 0.000 claims description 33
- 238000002591 computed tomography Methods 0.000 claims description 33
- 238000003745 diagnosis Methods 0.000 claims description 31
- 238000002601 radiography Methods 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 13
- 238000007689 inspection Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 140
- 238000004458 analytical method Methods 0.000 description 82
- 241001515965 unidentified phage Species 0.000 description 62
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 201000010099 disease Diseases 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 238000002493 microarray Methods 0.000 description 23
- 210000004072 lung Anatomy 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 230000003211 malignant effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 238000010606 normalization Methods 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 230000000391 smoking effect Effects 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000000505 pernicious effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000701867 Enterobacteria phage T7 Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000011049 pearl Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000009534 blood test Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102000018546 Paxillin Human genes 0.000 description 5
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 5
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102100029907 Exocyst complex component 6B Human genes 0.000 description 4
- 101001011230 Homo sapiens Exocyst complex component 6B Proteins 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102100040578 G antigen 7 Human genes 0.000 description 3
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012882 sequential analysis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000015335 Ku Autoantigen Human genes 0.000 description 2
- 108010025026 Ku Autoantigen Proteins 0.000 description 2
- 108091007767 MALAT1 Proteins 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 101100460147 Sarcophaga bullata NEMS gene Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 102000003970 Vinculin Human genes 0.000 description 2
- 108090000384 Vinculin Proteins 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007435 diagnostic evaluation Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000013274 transthoracic needle biopsy Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241000210651 Enterobacteria phage 1 Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 102100022726 Nucleolar and coiled-body phosphoprotein 1 Human genes 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108091027076 Spiegelmer Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000003050 experimental design method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73541805P | 2005-11-10 | 2005-11-10 | |
| US73555505P | 2005-11-10 | 2005-11-10 | |
| US60/735,418 | 2005-11-10 | ||
| US60/735,555 | 2005-11-10 | ||
| US80677806P | 2006-07-08 | 2006-07-08 | |
| US60/806,778 | 2006-07-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200680050765XA Division CN101374962A (zh) | 2005-11-10 | 2006-11-10 | 肺癌的诊断分析法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103245784A true CN103245784A (zh) | 2013-08-14 |
Family
ID=38228904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100906331A Pending CN103245784A (zh) | 2005-11-10 | 2006-11-10 | 肺癌的诊断分析法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20090197285A1 (enExample) |
| EP (1) | EP1952157A4 (enExample) |
| JP (1) | JP2009516178A (enExample) |
| KR (1) | KR20080073740A (enExample) |
| CN (1) | CN103245784A (enExample) |
| AU (1) | AU2006332597A1 (enExample) |
| BR (1) | BRPI0619712A2 (enExample) |
| CA (1) | CA2632190A1 (enExample) |
| WO (1) | WO2007079284A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116312739A (zh) * | 2021-12-20 | 2023-06-23 | 博尔诚（北京）科技有限公司 | 基于甲基化测序的标志物筛选方法、癌症检测方法及装置 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2652043A1 (en) * | 2006-05-12 | 2007-11-22 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
| KR101018665B1 (ko) | 2008-08-18 | 2011-03-04 | 재단법인서울대학교산학협력재단 | 전립선암 진단 방법 및 장치 |
| MX355020B (es) * | 2010-07-09 | 2018-04-02 | Somalogic Inc | Biomarcadores de cancer de pulmon y usos de los mismos. |
| JP5931874B2 (ja) | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| EP2660597B1 (en) * | 2010-12-28 | 2017-09-13 | ARKRAY, Inc. | Method for determining condition of oral cavity and analytical tool, apparatus and program used for the method |
| EP2780714B1 (en) | 2011-11-15 | 2017-08-16 | University Of Miami | Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma |
| WO2016013400A1 (ja) * | 2014-07-24 | 2016-01-28 | 国立大学法人 長崎大学 | 肺癌診断用バイオマーカー |
| CN110579611B (zh) * | 2019-09-18 | 2023-01-31 | 郑州大学 | 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法 |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351824A (en) * | 1981-02-05 | 1982-09-28 | Icl Scientific | Polystyrene latex reagents, methods of preparation, and use in immunological procedures |
| AU632469B2 (en) * | 1988-04-04 | 1993-01-07 | Johns Hopkins University, The | A method for early detection of lung cancer |
| CA2665707C (en) * | 1997-06-26 | 2013-02-12 | The Regents Of The University Of Michigan | Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum |
| GB9810040D0 (en) * | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
| GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
| EP1259545A2 (en) * | 2000-01-21 | 2002-11-27 | Ludwig Institute For Cancer Research | Small cell lung cancer associated antigens and uses therefor |
| JP2001343389A (ja) * | 2000-03-30 | 2001-12-14 | Nippon Kayaku Co Ltd | Ｍｄｍ２に対する自己抗体の測定によるがんの検査方法およびその試薬 |
| CA2462216A1 (en) * | 2001-11-09 | 2003-08-07 | Benaroya Research Institute At Virginia Mason | Antigen panels and methods of using the same |
-
2006
- 2006-11-10 KR KR1020087013907A patent/KR20080073740A/ko not_active Withdrawn
- 2006-11-10 EP EP06849131A patent/EP1952157A4/en not_active Ceased
- 2006-11-10 US US12/093,082 patent/US20090197285A1/en not_active Abandoned
- 2006-11-10 CA CA002632190A patent/CA2632190A1/en not_active Abandoned
- 2006-11-10 CN CN2013100906331A patent/CN103245784A/zh active Pending
- 2006-11-10 WO PCT/US2006/060796 patent/WO2007079284A2/en not_active Ceased
- 2006-11-10 BR BRPI0619712-4A patent/BRPI0619712A2/pt not_active IP Right Cessation
- 2006-11-10 JP JP2008540361A patent/JP2009516178A/ja active Pending
- 2006-11-10 AU AU2006332597A patent/AU2006332597A1/en not_active Abandoned
-
2012
- 2012-03-26 US US13/430,474 patent/US20120231966A1/en not_active Abandoned
-
2013
- 2013-10-04 US US14/046,271 patent/US20140066329A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116312739A (zh) * | 2021-12-20 | 2023-06-23 | 博尔诚（北京）科技有限公司 | 基于甲基化测序的标志物筛选方法、癌症检测方法及装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006332597A1 (en) | 2007-07-12 |
| BRPI0619712A2 (pt) | 2011-10-11 |
| US20140066329A1 (en) | 2014-03-06 |
| US20120231966A1 (en) | 2012-09-13 |
| US20090197285A1 (en) | 2009-08-06 |
| CA2632190A1 (en) | 2007-07-12 |
| KR20080073740A (ko) | 2008-08-11 |
| EP1952157A2 (en) | 2008-08-06 |
| EP1952157A4 (en) | 2009-04-08 |
| WO2007079284A3 (en) | 2008-09-18 |
| JP2009516178A (ja) | 2009-04-16 |
| WO2007079284A2 (en) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103245784A (zh) | 肺癌的诊断分析法 | |
| KR20090034961A (ko) | 폐암 진단 검사 | |
| CN105755112B (zh) | 结肠直肠癌的诊断 | |
| CN107102142A (zh) | 检测腺癌的蛋白标志/标记 | |
| CN105917230B (zh) | 用于确定胰腺癌的方法、阵列和其用途 | |
| CN107064518A (zh) | 确定胰腺癌存在的方法、阵列以及用途 | |
| Li et al. | Driverless artificial intelligence framework for the identification of malignant pleural effusion | |
| CN107796942A (zh) | 用于肺癌诊断的复合生物标志物群、肺癌诊断用试剂盒、利用其的信息的方法及计算系统 | |
| US7892761B2 (en) | Protein markers for diagnosing stomach cancer and the diagnostic kit using them | |
| ES2641479T3 (es) | Sistemas y métodos para tratar, diagnosticar y predecir la respuesta a la terapia del cáncer de mama | |
| CN106680515B (zh) | 用于肺癌诊断的多分子标志物组合 | |
| CN101374962A (zh) | 肺癌的诊断分析法 | |
| El-Sharkawy et al. | Circulating tumor cells in breast cancer: a step toward precision medicine for real-time monitoring of metastasis | |
| US7611845B2 (en) | Serum levels of HER2/neu as an indicator of clinical state and prognosis of prostate cancer | |
| CN116087517B (zh) | 用于区分早期肺腺癌和良性肺疾病的多肽组合及其应用 | |
| CN119643871B (zh) | 一种用于进展期结直肠腺瘤检测的生物标志物及其应用 | |
| Yousif et al. | Novel Biomarkers in Histopathology: Implications for Diagnosis and Prognosis | |
| Liao et al. | Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management | |
| RU2843217C2 (ru) | Способ определения индивидуального риска развития рака легкого у больных хронической обструктивной болезнью легких | |
| MX2008006130A (en) | Lung cancer diagnostic assay | |
| Li et al. | Machine learning to identify lung cancer with tuberculosis from isolated tuberculosis | |
| CN118777605A (zh) | 一种用于胰腺癌早期诊断的生物标志物及检验试剂盒 | |
| CN119032274A (zh) | 特发性肺纤维化生物标志物及其生产和使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130814 |